From Nasdaq:
Pfizer Inc. on Friday said its cancer drug Sutent met the primary goal of a late-stage study that tested the treatment as an added therapy in treating patients who are at high risk of the most common type of kidney cancer. A Phase 3 trial showed the drug improved disease-free survival in patients with renal cell carcinoma who are at high risk for recurrence after surgery.
